留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

降脂药物的肝脏毒性及其防治策略研究进展

徐岩成 方一杰 阎澜 姜远英 曹永兵

徐岩成, 方一杰, 阎澜, 姜远英, 曹永兵. 降脂药物的肝脏毒性及其防治策略研究进展[J]. 药学实践与服务, 2014, 32(6): 412-415,464. doi: 10.3969/j.issn.1006-0111.2014.06.004
引用本文: 徐岩成, 方一杰, 阎澜, 姜远英, 曹永兵. 降脂药物的肝脏毒性及其防治策略研究进展[J]. 药学实践与服务, 2014, 32(6): 412-415,464. doi: 10.3969/j.issn.1006-0111.2014.06.004
XU Yancheng, FANG Yijie, YAN Lan, JIANG Yuanying, CAO Yongbing. Progress on the hepatotoxicity of lipid-lowering drugs and its prevention strategies[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 412-415,464. doi: 10.3969/j.issn.1006-0111.2014.06.004
Citation: XU Yancheng, FANG Yijie, YAN Lan, JIANG Yuanying, CAO Yongbing. Progress on the hepatotoxicity of lipid-lowering drugs and its prevention strategies[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 412-415,464. doi: 10.3969/j.issn.1006-0111.2014.06.004

降脂药物的肝脏毒性及其防治策略研究进展

doi: 10.3969/j.issn.1006-0111.2014.06.004

Progress on the hepatotoxicity of lipid-lowering drugs and its prevention strategies

  • 摘要: 肝脏毒性是降血脂药物治疗常见的毒副作用之一,其发生机制尚不完全清楚,大多数降血脂药物的毒副作用都是剂量依赖性的,而且在停药后都有明显的缓解与改善。高龄以及慢性疾病等都是诱发降血脂药物肝脏毒性的潜在因素。降血脂药物的肝脏损伤治疗暂无统一规范,临床应对策略以停药、非特异性保肝和对症治疗为主。研发低毒性或具有保肝作用的降血脂药物,尤其是中药及中药制剂是一个具有良好前景的发展方向。
  • [1] Grundy SM, Cleeman JI, Merz CN,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines[J]. J Am Coll Cardiol,2004,44(3):720-732.
    [2] Argo CK, Loria P, Caldwell SH, et al. Statins in liver disease: a molehill, an iceberg, or neither?[J]. Hepatology, 2008,48(2):662-669.
    [3] Talbert RL. Safety issues with statin therapy[J]. J Am Pharm Assoc,2006;46(4):479-488.
    [4] Vuppalanchi R, Chalasani N. Statins for hyperlipidemia in patients with chronic liver disease: are they safe?[J]. Clin Gastroenterol Hepatol,2006,4(7):838-839.
    [5] 李光明, 范建高. 慢性肝病患者应用他汀的安全性及疗效[J]. 中华肝脏病杂志,2010,18(5):328-330.
    [6] Cash J, Callender ME, McDougall NI, et al. Statin safety and chronic liver disease[J]. Int J Clin Pract,2008,62(12): 1831-1835.
    [7] Gupta NK, Lewis JH. Review article: the use of potentially hepatotoxic drugs in patients with liver disease[J]. Aliment Pharmacol Ther,2008,28(9): 1021-1041.
    [8] Jimenez-Alonso J, Osorio JM, Guierrez-Cabello F, et al. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus[J]. A Arch Intern Med,1999,159(15):1811-1812.
    [9] de Castro ML, Hermo JA, Baz A, et al. Acute cholestatic hepatitis afteratorvastatin reintroduction[J]. Gastroenterol Hepatol,2006,29(1):21-24.
    [10] Nakad A, Bataille L, Hamoir V, et al. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin[J]. Lancet,1999,353(9166):1763-1764.
    [11] Gershovich OE, Lyman AE. Liver function test abnormalities and pruritis in a patient treated with atorvastatin: case report and review of the literature[J]. Pharmacotherapy,2004,24(1):150-154.
    [12] Grimbert S, Pessayre D, Degott C, et al. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin[J]. Dig Dis Sci,1994,39(9):2032-2033.
    [13] Vuppalanchi R, Teal E. Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes[J]. Am J Med Sci,2005,329(2):62-65.
    [14] Ricaurte B, Guirguis A, Taylor HC, et al. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity[J]. Ann Pharmacother,2006,40(4):753-757.
    [15] Kanathur N, Mathai MG, Byrd RP Jr, et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis[J]. Tenn Med,2001,94(9):339-341.
    [16] Caldwell SH, Hespenheide EE, von Borstel RW. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin[J]. Dig Dis Sci,2001,46(2):376-378.
    [17] Ashar U, Desai D, Bhaduri A. Flutamide-induced hepatotoxicity with possible potentiation by simvastatin[J]. J Assoc Physicians India,2003,51(1):75-77.
    [18] Cornwell PD, De Souza AT, Ulrich RG. Profiling of hepatic gene expression in rats treated with fibric acid analogs[J]. Mutat Res,2004,549(12):131-145.
    [19] Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates[J]. Am J Cardiol,2004,94(7):935-938.
    [20] Grubisic-Cabo F, Vrdoljak E. Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy[J]. Med Oncol,2006,23(1):121-124.
    [21] Vogt A, Kassner U, Hostalek U, et al. NAUTILUS Study Group. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study[J]. Curr Med Res Opin,2006,22(2):417-425.
    [22] Henkin Y, Johnson KC, Segrest JP. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin[J]. JAMA,1990,264(2):241-243.
    [23] Moon YS, Kashyap ML. Niacin extended-release/lovastatin: combination therapy for lipid disorders[J]. Expert Opin Pharmacother,2002,3(12):1763-1771.
    [24] Coppola A, Brady PG, Nord HJ. Niacin-induced hepatotoxicity: unusual presentations[J]. South Med J,1994,87(1):30-32.
    [25] McKenney J. Niacin for dyslipidemia: considerations in product selection[J]. Am J Health Syst Pharm,2003,60(10):995-1005.
    [26] Stolk MF, Becx MC, Kuypers KC, et al. Severe hepatic side effects of ezetimibe[J]. Clin Gastroenterol Hepatol,2006,4(7):908-911.
    [27] Cruz-Fernandez JM, Bedarida GV, Adgey J, et al. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease[J]. Int J Clin Pract,2005,59(6):619-627.
    [28] Armani A, Toth PP. Colesevelam hydrochloride in the management of dyslipidemia[J]. Expert Rev Cardiovasc Ther,2006,4(3):283-291.
    [29] Sirmans SM, Beck JK, Banh HL, et al. Colestipol-induced hepatotoxicity[J]. Pharmacotherapy,2001,21(4):513-516.
    [30] Graf D, Kohlmann C, Haselow K, et al. Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and independent pathways in rat liver[J]. Hepatology,2006,44(5):1206-1217.
    [31] Brewer HB Jr. High-density lipoprotein: a new potential therapeutic target for the prevention of cardiovascular disease[J]. Arterioscler Thromb Vasc Biol,2004,24:387-391.
    [32] FDA Statement: Pfizer Stops All Torcetrapib Clinical Trials in Interest of Patient Safety[R].2006.
    [33] 彭颂兴, 黎玉容. 药物性肝损伤的病因与临床分析[J]. 临床医药实践,2012,21(8):586-587.
    [34] Kar kiner A,Temir G,Utku M,et al.The efficacy of nonoperative management in childhood blunt hepatic trauma[J]. Ulus Travma Derg,2005,11(2):128-133.
    [35] 王慧铭, 夏道宗, 夏 明,等. 香菇多糖降血脂作用及其机制的研究[J]. 浙江中西医结合杂志,2005,15(10):599-602.
    [36] 狄建彬,顾振纶,赵笑东,等. 姜黄素防治大鼠高脂性脂肪肝的研究[J]. 中草药,2010,41(8):1322-1326.
    [37] 段玉梅,单松波. 降血脂药物开发应用新进展[J]. 黑龙江医药,2004,17(6):449-451.
  • [1] 吴文丹, 梁琳, 唐颖, 倪海莱, 郭美丽.  青葙总皂苷对高血脂动物脂质代谢的影响 . 药学实践与服务, 2018, 36(6): 493-498. doi: 10.3969/j.issn.1006-0111.2018.06.004
    [2] 贾文斌, 刘超, 邹燕.  抗骨质疏松治疗药物研究的新进展 . 药学实践与服务, 2017, 35(6): 490-494,542. doi: 10.3969/j.issn.1006-0111.2017.06.003
    [3] 叶亚琳, 王玉亮, 王泽剑, 殷明, 辛海量, 张磊.  青蒿琥酯和熊果酸降血脂作用的最佳配比筛选 . 药学实践与服务, 2014, 32(3): 195-198. doi: 10.3969/j.issn.1006-0111.2014.03.008
    [4] 倪敏, 沈甫明.  肝脏缺血再灌注损伤发生机制及药物干预研究进展 . 药学实践与服务, 2011, 29(3): 179-180,211.
    [5] 李蔚.  醋酸曲普瑞林(达菲林)致过敏1例 . 药学实践与服务, 2009, 27(3): 164-164.
    [6] 魏显招, 田径, 陈盛新.  创伤疼痛的药物处理进展 . 药学实践与服务, 2008, (6): 401-404.
    [7] 王晓红.  中药调节血脂研究概况 . 药学实践与服务, 2007, (2): 73-77.
    [8] 李林鹏, 孙浚雯, 曹永兵, 任天舒, 姜远英, 孙德好.  金黄地鼠和大鼠高血脂模型的应用研究 . 药学实践与服务, 2007, (6): 369-371.
    [9] 杨朋彬, 张晓丽, 徐燕.  导致男性性功能障碍和促乳腺发育的药物 . 药学实践与服务, 2005, (4): @-@.
    [10] 欧阳斌, 刘科秋, 苗百超.  纳米技术对药效学的影响 . 药学实践与服务, 2003, (2): 85-87.
    [11] 史国兵.  白癜风的发病机制及其治疗药物的现状 . 药学实践与服务, 2003, (1): 8-10.
    [12] 陈磊, 康鲁平, 秦路平, 郑汉臣.  药物治疗失眠 . 药学实践与服务, 2003, (2): 67-70.
    [13] 黄枝优.  药物的矛盾效应 . 药学实践与服务, 2002, (4): 220-222.
    [14] 陆道生.  雷尼替丁与肝脏损害 . 药学实践与服务, 1994, (1): 17-18.
    [15] 李光辉, 周玉坤, 韩林.  环孢菌素在器官移植中的肝脏毒性作用 . 药学实践与服务, 1991, (1): 16-17.
    [16] 贾丹兵.  乙醇注射可缩小肝脏肿瘤 . 药学实践与服务, 1988, (4): 29-29.
    [17] 胡学智, 林一鸣.  降压药与血脂的关系 . 药学实践与服务, 1985, (3): 16-16.
    [18] EricJ·Lien.  药物副作用——耳毒性 . 药学实践与服务, 1984, (4): 49-52.
    [19] 李起, 李晓白.  长期服用谷维素对高血脂症的效果 . 药学实践与服务, 1984, (4): 46-46.
    [20] P.F.D'Arcy.  肝脏疾患与药物 . 药学实践与服务, 1983, (3): 60-61.
  • 加载中
计量
  • 文章访问数:  2163
  • HTML全文浏览量:  219
  • PDF下载量:  237
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-10-29
  • 修回日期:  2014-06-11

降脂药物的肝脏毒性及其防治策略研究进展

doi: 10.3969/j.issn.1006-0111.2014.06.004

摘要: 肝脏毒性是降血脂药物治疗常见的毒副作用之一,其发生机制尚不完全清楚,大多数降血脂药物的毒副作用都是剂量依赖性的,而且在停药后都有明显的缓解与改善。高龄以及慢性疾病等都是诱发降血脂药物肝脏毒性的潜在因素。降血脂药物的肝脏损伤治疗暂无统一规范,临床应对策略以停药、非特异性保肝和对症治疗为主。研发低毒性或具有保肝作用的降血脂药物,尤其是中药及中药制剂是一个具有良好前景的发展方向。

English Abstract

徐岩成, 方一杰, 阎澜, 姜远英, 曹永兵. 降脂药物的肝脏毒性及其防治策略研究进展[J]. 药学实践与服务, 2014, 32(6): 412-415,464. doi: 10.3969/j.issn.1006-0111.2014.06.004
引用本文: 徐岩成, 方一杰, 阎澜, 姜远英, 曹永兵. 降脂药物的肝脏毒性及其防治策略研究进展[J]. 药学实践与服务, 2014, 32(6): 412-415,464. doi: 10.3969/j.issn.1006-0111.2014.06.004
XU Yancheng, FANG Yijie, YAN Lan, JIANG Yuanying, CAO Yongbing. Progress on the hepatotoxicity of lipid-lowering drugs and its prevention strategies[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 412-415,464. doi: 10.3969/j.issn.1006-0111.2014.06.004
Citation: XU Yancheng, FANG Yijie, YAN Lan, JIANG Yuanying, CAO Yongbing. Progress on the hepatotoxicity of lipid-lowering drugs and its prevention strategies[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 412-415,464. doi: 10.3969/j.issn.1006-0111.2014.06.004
参考文献 (37)

目录

    /

    返回文章
    返回